Voriconazole(UK-109496) is a second-generation triazole antifungal used to treat serious fungal infections. IC50 Value: Target: Antifungal Voriconazole displays potent activity against Candida, Cryptococcus and Aspergillus species. Voriconazole inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-α sterol demethylase resulting in a depletion of ergosterol in fungal cell membranes.

• [1]. Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics. 2011 Jun;12(6):861-72. doi: 10.2217/pgs.11.18.

  [2]. Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009 Dec;68(6):906-15. doi: 10.1111/j.1365-2125.2009.03534.x.

  [3]. Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther. 2004 Aug;2(4):485-97.

  [4]. Louis D. Saravolatz, Section Editor, Leonard B. Johnson, et al. Voriconazole: A New Triazole Antifungal Agent. Clin Infect Dis. 2003,36 (5): 630-637.

  [5]. John R. Perfect, Kieren A. Marr, Thomas J. Walsh, et al. Voriconazole Treatment for Less-Common, Emerging, or Refractory Fungal Infections. Clin Infect Dis. 2003, 36 (9): 1122-1131.